GlaxoSmithKline Laval facility becomes North America vaccine research and development headquarters
$50 million investment to support new role
GlaxoSmithKline (GSK) has designated its facility in Laval, Quebec, as the North American headquarters of its innovative vaccines division. The site will conduct leading vaccine research & development (R&D), and is also the administrative centre for the company's vaccines operations in North America. To support this crucial new role, GSK has created more than 60 new high calibre jobs and is completing an investment of $50 million to expand and upgrade existing laboratory facilities, including the construction of a new state-of-the-art serology lab, clinical development and operational costs.
Scientists in Laval will focus research and development work in the areas of adjuvant technologies, molecular biology, immunology, respiratory viral vaccines, allergy, oncology and process development.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Portescap S.A. - La Chaux-de-Fonds, Switzerland

AGW Antech Gütling GmbH - Fellbach, Germany

Fermify GmbH - Vienna, Austria

ELITech Group - Puteaux, France
Merck KGaA restructured its pharmaceuticals business in Germany

Genofocus, Inc. - Daejeon, Korea, Republic of (South Korea)
